Journal Article

DZNE-2020-06224

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40.

Hampel, H. (Corresponding author) ; Toschi, N. ; Baldacci, F. ; Zetterberg, H. ; Blennow, K. ; Kilimann, I.DZNE* ; Teipel, S. J.DZNE* ; Cavedo, E. ; Melo Dos Santos, A. ; Epelbaum, S. ; Lamari, F. ; Genthon, R. ; Dubois, B. ; Floris, R. ; Garaci, F. ; Lista, S. ; Initiative, A. P. M.

2018
Elsevier Amsterdam [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/j.jalz.2017.11.015

Abstract: The diagnostic and classificatory performances of all combinations of three core (amyloid β peptide [i.e., Aβ1-42], total tau [t-tau], and phosphorylated tau) and three novel (neurofilament light chain protein, neurogranin, and YKL-40) cerebrospinal fluid biomarkers of neurodegeneration were compared among individuals with mild cognitive impairment (n = 41), Alzheimer's disease dementia (ADD; n = 35), frontotemporal dementia (FTD; n = 9), and cognitively healthy controls (HC; n = 21), using 10-fold cross-validation.The combinations ranking in the top 10 according to diagnostic accuracy in differentiating between distinct diagnostic categories were identified.The single biomarkers or biomarker combinations generating the best area under the receiver operating characteristics (AUROCs) were the following: the combination [amyloid β peptide + phosphorylated tau + neurofilament light chain] for distinguishing between ADD patients and HC (AUROC = 0.86), t-tau for distinguishing between ADD and FTD patients (AUROC = 0.82), and t-tau for distinguishing between FTD patients and HC (AUROC = 0.78).Novel and established cerebrospinal fluid markers perform with at least fair accuracy in the discrimination between ADD and FTD. The classification of mild cognitive impairment individuals was poor.

Keyword(s): Aged (MeSH) ; Alzheimer Disease: cerebrospinal fluid (MeSH) ; Alzheimer Disease: classification (MeSH) ; Amyloid beta-Peptides: cerebrospinal fluid (MeSH) ; Area Under Curve (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Chitinase-3-Like Protein 1: cerebrospinal fluid (MeSH) ; Cognitive Dysfunction: cerebrospinal fluid (MeSH) ; Cognitive Dysfunction: classification (MeSH) ; Cross-Sectional Studies (MeSH) ; Diagnosis, Differential (MeSH) ; Female (MeSH) ; Frontotemporal Dementia: cerebrospinal fluid (MeSH) ; Frontotemporal Dementia: classification (MeSH) ; Humans (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Neurofilament Proteins: cerebrospinal fluid (MeSH) ; Nuclear Proteins: cerebrospinal fluid (MeSH) ; Peptide Fragments: cerebrospinal fluid (MeSH) ; RNA-Binding Proteins (MeSH) ; ROC Curve (MeSH) ; Retrospective Studies (MeSH) ; tau Proteins: cerebrospinal fluid (MeSH) ; Amyloid beta-Peptides ; Biomarkers ; CHI3L1 protein, human ; Chitinase-3-Like Protein 1 ; MAPT protein, human ; NGDN protein, human ; Neurofilament Proteins ; Nuclear Proteins ; Peptide Fragments ; RNA-Binding Proteins ; amyloid beta-protein (1-42) ; neurofilament protein L ; tau Proteins

---

Contributing Institute(s):

1. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)

Research Program(s):

1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)

Appears in the scientific report 2018

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; IF >= 15 ; JCR ; SCOPUS ; Web of Science Core Collection

---